RADIANT-4: everolimus for advanced non-functional neuroendocrine tumours of the lung or gastrointestinal tract
Everolimus more than doubled the time to progression in advanced non-functioning neuroendocrine tumours of the lung and gut, the first drug with randomised evidence in lung carcinoids.
Overview
Phase 3 placebo-controlled trial of 302 patients with advanced progressive, well-differentiated, non-functional neuroendocrine tumours of lung or gastrointestinal origin randomised 2:1 to everolimus 10 mg daily or placebo.
Median progression-free survival was 11.0 versus 3.9 months (hazard ratio 0.48), with consistent benefit in lung and gastrointestinal subgroups; stomatitis, diarrhoea and infections were the main toxicities.
- Median progression-free survival 11.0 vs 3.9 months; hazard ratio 0.48.
- Lung subgroup: 9.2 vs 3.6 months.
Everolimus is approved for progressive lung and gastrointestinal neuroendocrine tumours and is a standard option after somatostatin analogues, particularly in lung carcinoids where radioligand therapy is off label.
- No overall survival benefit shown.
- Response rates were low; benefit is disease stabilisation.
Similar pages
not linked directly; found by shared links- TrialRADIANT-3 and RADIANT-4
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours, Everolimus.
- TermCarcinoid syndrome and carcinoid heart disease
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours.
- Key paperCABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours.
- TrialZanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours.
- TermChromogranin A
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours.
- TrialStudy to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours.
- TrialCABINET (Alliance A021602)
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours.
- TermNeuroendocrine tumour grade (Ki-67) and WHO classification
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours.